Windlas Biotech Limited (BOM:543329)
993.25
+7.95 (0.81%)
At close: Aug 21, 2026
Windlas Biotech Revenue
Windlas Biotech had revenue of 2.48B INR in the quarter ending June 30, 2026, with 18.09% growth. This brings the company's revenue in the last twelve months to 9.42B, up 18.53% year-over-year. In the fiscal year ending March 31, 2026, Windlas Biotech had annual revenue of 9.04B with 18.98% growth.
Revenue (ttm)
9.42B
Revenue Growth
+18.53%
P/S Ratio
2.18
Revenue / Employee
6.80M
Employees
1,385
Market Cap
20.50B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 9.04B | 1.44B | 18.98% |
| Mar 31, 2025 | 7.60B | 1.29B | 20.43% |
| Mar 31, 2024 | 6.31B | 1.18B | 22.97% |
| Mar 31, 2023 | 5.13B | 471.53M | 10.12% |
| Mar 31, 2022 | 4.66B | 383.28M | 8.96% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hikal | 17.35B |
| TTK Healthcare | 8.88B |
| Venus Remedies | 8.11B |
| Fredun Pharmaceuticals | 7.44B |
| Lincoln Pharmaceuticals | 6.94B |
| Kwality Pharmaceuticals | 5.54B |
| Amrutanjan Health Care | 5.11B |
| Fermenta Biotech | 5.11B |